|Bid||0.9500 x 800|
|Ask||0.9900 x 900|
|Day's range||0.9333 - 1.0201|
|52-week range||0.9333 - 4.5400|
|Beta (5Y monthly)||1.84|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||18 Dec 2012|
|1y target est||N/A|
Investors need to pay close attention to Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.
The heavy selling pressure might have exhausted for Spectrum Pharma (SPPI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Joining me on the call today from Spectrum Pharmaceuticals will be Joe Turgeon, President and CEO; and Dr. Francois Lebel, our Chief Medical Officer. Before we get started, I would like to reference the notice regarding forward-looking statements included in today's press release.